The Current Treatment for Neurodegenerative Diseases
- 1 School of Life Science, Nanjing University, Nanjing, China.
* Author to whom correspondence should be addressed.
Abstract
Neurodegenerative diseases (NDs) refer to dysfunction of central nerve system, characterized by progressive loss of neuronal structure and function, ultimately resulting in decline in patients’ memory, motor ability, language and intelligence. The typical NDs include age related diseases like Aleimer’s disease (AD) and genetic diseases such as Huntington’s diseases (HD) and amyotrophic lateral sclerosis (ALS). NDs impose heavy economic burden and suffer to the enormous patients over the world, however, many types of NDs do not have a cure; existing treatments only aim to improve their symptoms. Under that condition, Gene therapy has shown potential for transporting some genetic products into the cells and correct faulty genes. Over the years, research have highlighted the promise of gene therapies using AAV vector in treating NDs. At the same time, a number of emerging therapeutic technologies for neurodegenerative diseases, such as epigenetic interventions through acetylation/deacetylation, gene therapies that target specific mRNAs or non-coding RNAs, and photo biomodulation therapies that can act on brain tissue, are also being studied. In this discussion, we explore the historical, present, and future outlook of gene therapies for neurodegenerative conditions.
Keywords
Neurodegenerative disease, treatment, CAR-T, AAV
[1]. Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, et al. . Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study [J]. Lancet Public Health,2020,5:e661-71.
[2]. Yang L. Research progress on pathogenesis, early intervention and treatment of Alzheimer's disease [J].Advances in Biomedical Engineering,2024,45(01):14-20.
[3]. Wang J, Chen S, Gao X. Research progress on Alzheimer's disease targets and related drugs [J]. Pharmaceutical Biotechnology,2021,28(03):323-330.
[4]. Xue F, Jia Y, Li F. Correlation between regulatory T cell, IL-10 and TGF-β1 expression and recurrence of human glioma [J].China Health Engineering,2020,19(03):419-421.
[5]. Lin Y, Raje NS, Berdeja JG, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial [J]. Nat Med,2023;29(9):2286-2294.
[6]. Wang D. Anti-tumor study on the preparation of recombinant adeno-associated virus targeting CD19 antigen CAR-T cells [D].University of Science and Technology of China,2022.
[7]. Zhang Z, Lin K, Xu F, et al. Research progress on AAV vector optimization in DMD gene therapy [J].Life Sciences,2024,36(03):373-380.
[8]. Qian Z, Dong Q, Hongyu C, et al. Research progress of ApoE in Alzheimer's disease [J]. Stroke and Neurological Diseases,2024,31(02):143-147+166.
[9]. Shimada M, Abe S, Takahashi T, et al. Prophylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein [J]. PLoS One,2013,8(3):e57606.
[10]. Pei Z, Wu T. Advances in gene therapy for Huntington's disease [J]. Journal of Chongqing Medical University,2024,49(05):552-557.
[11]. Peng Y. Construction of a mouse model of Huntington's disease (HD) knock-in in situ using CRISPR/Cas9 technology [D].Southwest University,2019.
[12]. Hutvagner G, Simard MJ. Argonaute proteins: key players in RNA silencing [J]. Nat Rev Mol Cell Biol,2008,9(1):22-32.
[13]. Huang W, Lin H, Guo Z, et al. Research progress and prospects of gene therapy for Huntington's disease [J]. Chinese Journal of Neurology,2023,22(11):1160-1163.
Cite this article
Li,Z. (2024).The Current Treatment for Neurodegenerative Diseases.Theoretical and Natural Science,54,82-87.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content
About volume
Volume title: Proceedings of ICBioMed 2024 Workshop: Workshop on Intelligent Medical Data Analysis for Precision Medicine
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).